91 related articles for article (PubMed ID: 8630414)
21. Generation of dendritic cells from peripheral blood of patients at different stages of chronic myeloid leukemia.
Zheng C; Pisa P; Stromberg O; Blennow E; Hansson M
Med Oncol; 2000 Nov; 17(4):270-8. PubMed ID: 11114705
[TBL] [Abstract][Full Text] [Related]
22. In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission.
Somasundaram R; Rao SG; Advani SH; Gangal SG
Cancer Immunol Immunother; 1988; 27(2):177-82. PubMed ID: 3262014
[TBL] [Abstract][Full Text] [Related]
23. GMP-compliant, large-scale expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells in vitro and in vivo.
Lim O; Lee Y; Chung H; Her JH; Kang SM; Jung MY; Min B; Shin H; Kim TM; Heo DS; Hwang YK; Shin EC
PLoS One; 2013; 8(1):e53611. PubMed ID: 23326467
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-2 and interleukin-7 augment the cytolytic activity and expand the antitumor killing spectrum of alpha CD3-induced activated killer cells: potential use in the immunotherapy of non-immunogenic tumors.
Ting CC; Wang J; Yang Y
Cancer Immunol Immunother; 1996 Dec; 43(5):283-92. PubMed ID: 9024505
[TBL] [Abstract][Full Text] [Related]
25. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
[TBL] [Abstract][Full Text] [Related]
26. Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-alpha 2a and interleukin-2.
Morecki S; Revel-Vilk S; Nabet C; Pick M; Ackerstein A; Nagler A; Naparstek E; Ben Shahar M; Slavin S
Cancer Immunol Immunother; 1992; 35(6):401-11. PubMed ID: 1394343
[TBL] [Abstract][Full Text] [Related]
27. Low c-Kit expression identifies primitive, therapy-resistant CML stem cells.
Shah M; Kumar H; Qiu S; Li H; Harris M; He J; Abraham A; Crossman DK; Paterson A; Welner RS; Bhatia R
JCI Insight; 2023 Jan; 8(1):. PubMed ID: 36413413
[TBL] [Abstract][Full Text] [Related]
28. Lysis of fresh human solid tumor cells by autologous lymphocytes activated in vitro by allosensitization.
Mazumder A; Grimm EA; Rosenberg SA
Cancer Immunol Immunother; 1983; 15(1):1-10. PubMed ID: 6603260
[TBL] [Abstract][Full Text] [Related]
29. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
Parkhurst MR; Riley JP; Dudley ME; Rosenberg SA
Clin Cancer Res; 2011 Oct; 17(19):6287-97. PubMed ID: 21844012
[TBL] [Abstract][Full Text] [Related]
30. Activation of human T-helper/inducer cell, T-cytotoxic cell, B-cell, and natural killer (NK)-cells and induction of natural killer cell activity against K562 chronic myeloid leukemia cells with modified citrus pectin.
Ramachandran C; Wilk BJ; Hotchkiss A; Chau H; Eliaz I; Melnick SJ
BMC Complement Altern Med; 2011 Aug; 11():59. PubMed ID: 21816083
[TBL] [Abstract][Full Text] [Related]
31. Autologous control of a highly malignant syngeneic CRNK-16 leukemia in the rat: a role for NK cells.
Avraham R; Inbar S; Rosenne E; Ben-Eliyahu S
Cancer Immunol Immunother; 2006 Nov; 55(11):1348-57. PubMed ID: 16465528
[TBL] [Abstract][Full Text] [Related]
32. Induction of cytotoxicity against autologous tumour cells by interleukin-12: evidence for intrinsic anti-tumor immune capacity in curatively resected gastrointestinal tumour patients.
Ströhlein MA; Grützner KU; Schildberg FW; Heiss MM
Cancer Immunol Immunother; 2002 Nov; 51(9):505-12. PubMed ID: 12357322
[TBL] [Abstract][Full Text] [Related]
33. Human T-cell cultures with selective autotumor reactivity.
Vánky F; Klein E
Cancer Immunol Immunother; 1982; 14(2):73-7. PubMed ID: 6985460
[TBL] [Abstract][Full Text] [Related]
34. Long-term serum/plasma-free culture of human cytotoxic T lymphocytes induced from peripheral blood mononuclear cells.
Liu SQ; Shiba R; Kim BS; Saijo K; Ohno T
Cancer Immunol Immunother; 1994 Nov; 39(5):279-85. PubMed ID: 7987858
[TBL] [Abstract][Full Text] [Related]
35. NK cells in allogeneic bone marrow transplantation.
Voutsadakis IA
Cancer Immunol Immunother; 2003 Sep; 52(9):525-34. PubMed ID: 14627124
[TBL] [Abstract][Full Text] [Related]
36. Cytokine-Induced Memory-Like NK Cells with High Reactivity against Acute Leukemia Blasts and Solid Tumor Cells Suitable for Adoptive Immunotherapy Approaches.
Tanzi M; Consonni M; Falco M; Ferulli F; Montini E; Pasi A; Cacciatore R; Brugnatelli S; Pedrazzoli P; Zecca M; Boghen S; Dellabona P; Casorati G; Montagna D
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808051
[TBL] [Abstract][Full Text] [Related]
37. Upregulation of thioredoxin-1 in activated human NK cells confers increased tolerance to oxidative stress.
Mimura K; Kua LF; Shimasaki N; Shiraishi K; Nakajima S; Siang LK; Shabbir A; So J; Yong WP; Kono K
Cancer Immunol Immunother; 2017 May; 66(5):605-613. PubMed ID: 28224212
[TBL] [Abstract][Full Text] [Related]
38. Cellular immunological defects of chronic myelogenous leukaemics: partial dependence on busulphan therapy.
Pawelec G; Schmidt H; Schneider E; Bühring HJ; Ehninger G
Cancer Immunol Immunother; 1988; 27(1):89-94. PubMed ID: 2969285
[TBL] [Abstract][Full Text] [Related]
39. IL-27 impact on NK cells activity: Implication for a robust anti-tumor response in chronic lymphocytic leukemia.
Hemati M; Rasouli Nejad Z; Shokri MR; Ghahremanfard F; Mir Mohammadkhani M; Kokhaei P
Int Immunopharmacol; 2020 Feb; 82():106350. PubMed ID: 32120343
[TBL] [Abstract][Full Text] [Related]
40. Successful treatment of smouldering Human T cell Leukemia Virus Type1 associated bronchiolitis and alveolar abnormalities with amplified natural killer therapy.
Nagai K; Nagai S; Hara Y
BMJ Case Rep; 2021 Dec; 14(12):. PubMed ID: 34876443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
